Glucocorticoid use in psoriatic arthritis and treatment outcomes: does the gender have a role?

Egyptian Rheumatology and Rehabilitation

Table 2 Multiple regression analysis for glucocorticoid use

Variable	p	OR/β coefficient	95.0% confidence ınterval
Variable	p	OR/β coefficient	Lower bound	Upper bound
Gender	0.06	0.63	0.367	1.1
DIP involvement	0.161	1.75	0.72	4.28
Enthesitis	0.522	1.09	0.44	2.70
Dactylitis	0.042	3.12	0.98	9.89
Axial involvement	0.365	1.19	0.63	2.26
Sacroiliitis (uni-bilateral)	0.248	0.68	0.301	1.55
Nail psoriasis	0.33	0.521	0.109	2.49
Pustular psoriasis	0.351	0.39	0.04	3.407
CRP	0.004	0.299	0.004	0.019
DAS-28	0.366	0.227	− 0.195	0.526
DAPSA	0.331	− 0.231	− 0.047	0.016
Uric acid (mg/dL)	0.134	0.124	− 0.012	0.087

Analysis adjusted for age and symptom duration. DIP distal interphalangeal joint, CRP C reactive protein, DAS-28 disease activity score-28, DAPSA Disease Activity Index for Psoriatic Arthritis, OR odds ratio
*Significance (P ≤ 0.05 is statistically significant)